PLIANT THERAPEUTICS INC

PLRXNASDAQ

🏆 #4313 by market capEarnings Nov 4US Equity

$1.08▲ $0.00 (+0.00%)

After hours · at close

🔔

Track PLRX

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 0.0%

7d▼ 4.4%

14d▼ 3.6%

30d▼ 2.7%

ytd▼ 10.7%

1y▼ 27.5%

🏦Market Cap

$67M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $1.07 – $1.10
52-Week Range: $1.02 – $1.95
Volume: $3.84B
Avg Volume: $2.60B
Shares Outstanding: 61.9M
Next Earnings: Oct 27, 2026

Fundamentals Snapshot

Annual Revenue: $10M
Last Q Revenue: $3M
P/E Ratio: -0.7
P/S Ratio: 0.0x
EPS (TTM): $-1.49
Dividend Yield: 0.00%
Dilution (1yr): +1.4%

Why Investors Own PLRX

✓High-growth profile — revenue up -0.7% YoY with expanding US Equity exposure.
✓Healthy economics — 28% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PLIANT THERAPEUTICS INC

PLRX

Financial Trends

Revenue

$0▲ +0.0% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$150M▼ −34.3% YoY

Free Cash Flow

−$129M▼ −19.2% YoY

Shares Outstanding

61.4M▲ +1.4% YoY

Net Cash

$16M▲ +$5M YoY

StockOtter · stockotter.space

About PLIANT THERAPEUTICS INC

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.

🦦